Related Experiment Video
Updated: Mar 21, 2026
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
NU7441 Enhances the Radiosensitivity of Liver Cancer Cells
Objective:
Radiation therapy, one of the major treatments for liver cancer, causes DNA damage and cell death. Since the liver cancer cells have a strong capacity to repair irradiative injury, new medicines to enhance this treatment are urgently required. In this study, we investigated the effect of NU7441, a synthetic small-molecule compound, as a specific inhibitor of DNA-dependent protein kinase (DNA-PK) in radiosensitization of hepatocellular carcinoma HepG2 cells.
Methods:
Cell Counting Kit-8 (CCK-8) was first used to evaluate the proliferation of HepG2 cells under NU7441 treatment. SDS-PAGE and Western blot were then performed to study the protein expression leading to the DNA damage repair. Further, neutral single cell gel electrophoresis and immunofluorescence assay were carried out to assess DNA repair. Finally, flow cytometry was implemented to examine the changes in cell cycle.
Results:
NU7441 reduced the CCK-8 counts in the HepG2 culture, further enhanced 60Cox03B3; radiation injury to HepG2 cells, which was manifested by decreasing the DNA-PKcs (S2056) protein expression, increasing x03B3;H2AX foci number, prolonging the tail moment of the comet cells, and inducing cell cycle arrest at G2/M phase.
Conclusion:
NU7441 inhibited the growth of liver cancer cells, enhanced the radiosensitization of these cancer cells by interfering with the DNA repair and cell cycle checkpoint. These data implicate NU7441 as a potential radiotherapy sensitizer for the treatment of liver cancer.
Insights
NU7441, a DNA-PK inhibitor, enhances liver cancer cell radiosensitivity by hindering DNA repair and cell cycle progression. This compound shows potential as a radiotherapy sensitizer for hepatocellular carcinoma treatment.
Area of Science:
- Oncology
- Molecular Biology
- Radiotherapy
Background:
- Hepatocellular carcinoma (HCC) treatment relies on radiation therapy, which induces DNA damage.
- HCC cells possess robust DNA repair mechanisms, limiting radiotherapy efficacy.
- Novel agents are needed to overcome radioresistance in liver cancer.
Purpose of the Study:
- To investigate NU7441, a DNA-dependent protein kinase (DNA-PK) inhibitor, as a radiosensitizer for HCC.
- To evaluate the impact of NU7441 on DNA repair pathways and cell cycle progression in HepG2 cells.
Main Methods:
- Cell Counting Kit-8 (CCK-8) assay for cell proliferation.
- SDS-PAGE and Western blot for protein expression analysis.
- Neutral single cell gel electrophoresis and immunofluorescence for DNA damage assessment.
- Flow cytometry for cell cycle analysis.
Main Results:
- NU7441 reduced HepG2 cell viability and enhanced radiation-induced injury.
- NU7441 decreased DNA-PKcs phosphorylation and increased γH2AX foci.
- Comet assay revealed prolonged DNA tail moments, indicating impaired repair.
- Flow cytometry showed NU7441 induced G2/M phase cell cycle arrest.
Conclusions:
- NU7441 effectively inhibits HCC cell growth and enhances radiosensitivity.
- The compound interferes with DNA repair and cell cycle checkpoints.
- NU7441 is a promising candidate as a radiotherapy sensitizer for liver cancer.
